While other current marketed DPP-4 inhibitors are dosed once or more than once per day, trelagliptin showed efficacy as well as a suitable safety profile in T2DM patients by dosing once-weekly in a clinical trial setting [2, 5]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.